- Home
- IBIO vs CODX Comparison
IBIO vs CODX Comparison
Compare IBIO & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- CODX
- Stock Information
- Founded
- IBIO 2008
- CODX 2013
- Country
- IBIO United States
- CODX United States
- Employees
- IBIO N/A
- CODX N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- CODX Medical/Dental Instruments
- Sector
- IBIO Health Care
- CODX Health Care
- Exchange
- IBIO Nasdaq
- CODX Nasdaq
- Market Cap
- IBIO 24.3M
- CODX 22.0M
- IPO Year
- IBIO N/A
- CODX 2017
- Fundamental
- Price
- IBIO $0.76
- CODX $0.35
- Analyst Decision
- IBIO Strong Buy
- CODX Hold
- Analyst Count
- IBIO 3
- CODX 1
- Target Price
- IBIO $4.87
- CODX $1.00
- AVG Volume (30 Days)
- IBIO 1.2M
- CODX 202.3K
- Earning Date
- IBIO 05-12-2025
- CODX 05-08-2025
- Dividend Yield
- IBIO N/A
- CODX N/A
- EPS Growth
- IBIO N/A
- CODX N/A
- EPS
- IBIO N/A
- CODX N/A
- Revenue
- IBIO $375,000.00
- CODX $3,915,160.00
- Revenue This Year
- IBIO $36.00
- CODX N/A
- Revenue Next Year
- IBIO $33.33
- CODX N/A
- P/E Ratio
- IBIO N/A
- CODX N/A
- Revenue Growth
- IBIO 650.00
- CODX N/A
- 52 Week Low
- IBIO $0.87
- CODX $0.28
- 52 Week High
- IBIO $6.89
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- IBIO 19.10
- CODX 42.85
- Support Level
- IBIO $0.64
- CODX $0.32
- Resistance Level
- IBIO $1.00
- CODX $0.38
- Average True Range (ATR)
- IBIO 0.32
- CODX 0.05
- MACD
- IBIO -0.10
- CODX 0.01
- Stochastic Oscillator
- IBIO 3.55
- CODX 64.17
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.